| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = -$1 ) |
| 2024 | 2023 | RESBIOTIC | 1500 1ST AVE N | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 000 | 1 | NIH | 2/16/2024 | -$1 |
|
| Issue Date FY: 2023 ( Subtotal = $295,274 ) |
| 2023 | 2023 | RESBIOTIC | 1500 1ST AVE N | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 001 | 1 | NIH | 6/21/2023 | $0 |
| 2023 | 2023 | RESBIOTIC | 1500 1ST AVE N | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 002 | 1 | NIH | 9/8/2023 | -$3,297 |
| 2023 | 2023 | RESBIOTIC | 1500 1ST AVE N | BIRMINGHAM | AL | 35203-1865 | JEFFERSON | USA | R44HL164156 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD | 000 | 1 | NIH | 2/15/2023 | $298,571 |
|
|